Roivant Lung Drug Succeeds in Mid-Stage Study
Roivant reported that its experimental drug mosliciguat met the main goals in a mid-stage study for pulmonary hypertension associated with lung disease. The treatment significantly reduced blood vessel resistance and improved patient mobility.
Xurve View
Insights:
Xurve View